(Q44397527)

2 December 2017

1 reference

title

Early diagnosis of invasive fungal infections caused by Aspergillus and other emerging mycelial fungi (English)

1 reference

invasive fungal infections

2 December 2017

main subject

1 reference

Amalia del Palacio

1

1 reference

2 December 2017

Almudena Alhambra

series ordinal

2

1 reference

2 December 2017

María Soledad Cuétara

series ordinal

3

1 reference

2 December 2017

José Pontón

series ordinal

4

1 reference

2 December 2017

publication date

1 September 2007

1 reference

Revista iberoamericana de micologia

2 December 2017

published in

1 reference

2 December 2017

volume

24

1 reference

2 December 2017

issue

3

1 reference

2 December 2017

page(s)

187-197

1 reference

Trial design for mold-active agents: time to break the mold--aspergillosis in neutropenic adults

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Detection of Aspergillus galactomannan antigenemia to determine biological and clinical implications of beta-lactam treatments

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Invasive aspergillosis due to subungual onychomycosis during treatment for non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Cryptococcus neoformans Galactoxylomannan contains an epitope(s) that is cross-reactive with Aspergillus Galactomannan

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Should the consensus guidelines' specific criteria for the diagnosis of invasive fungal infection be changed?

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Between over- and undertreatment of invasive fungal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

[Risk factors in invasive candidiasis: stratification]

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

(1-->3)-Beta-D-glucans and respiratory health: a review of the scientific evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Discordant rise in galactomannan antigenemia in a patient with resolving Aspergillosis, renal failure, and ongoing hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Clinical and radiologic predictors of invasive pulmonary aspergillosis in cancer patients: should the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) criteria be revised?

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Laboratory diagnosis of invasive aspergillosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

The invasive and saprophytic syndromes due to Aspergillus spp.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Gelation of limulus amoebocyte lysate by an antitumor (1→3)-β-D-glucan

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Elevation of blood (1-->3)-beta-D-glucan concentrations in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1-->3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Critical assessment of issues in the diagnosis of invasive aspergillosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Detection of gliotoxin in experimental and human aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Frequency and species distribution of gliotoxin-producing Aspergillus isolates recovered from patients at a tertiary-care cancer center

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Preemptive antifungal therapy: still a way to go.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Defining a case of invasive aspergillosis by serum galactomannan

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Design issues in studies evaluating diagnostic tests for aspergillosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

The use of a risk group stratification in the management of invasive fungal infection: a prospective validation

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Invasive aspergillosis in critically ill patients without malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

False positivity for Aspergillus antigenemia with amoxicillin-clavulonic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

When a paradoxical increase in serum galactomannan antigen during caspofungin therapy is not paradoxical after all

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Incidence of invasive fungal infection in adult haematological malignancy: a prospective validation of a risk stratification scheme

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

False-positive results of Aspergillus enzyme-linked immunosorbent assays for a patient with gastrointestinal graft-versus-host disease taking a nutrient containing soybean protein

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Diagnostic potential of (1,3)-beta-D-glucan and anti-Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Contribution of (1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Influence of Candida colonization on the (1-->3) beta-D-glucan assay

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Towards a targeted, risk-based, antifungal strategy in neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Galactomannan and the diagnosis of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Changing patterns and trends in systemic fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Epidemiology and outcome of zygomycosis: a review of 929 reported cases

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Aspergillus infections in transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Reproducibility of low galactomannan enzyme immunoassay index values tested in multiple laboratories

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

(1-->3) beta -D-glucan assay in the diagnosis of invasive fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Aspergillosis in the ICU - The new 21st century problem?

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Advances in diagnostic testing

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Galactomannan Does Not Precede Major Signs on a Pulmonary Computerized Tomographic Scan Suggestive of Invasive Aspergillosis in Patients with Hematological Malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

Infectious diseases and the autopsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2807%2970042-6

7 January 2021

10.1016/S1130-1406(07)70042-6

Identifiers

DOI

1 reference

2 December 2017

1 reference